Rostislav Christov Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 2,431 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of C$9.66, for a total value of C$23,476.17.

Rostislav Christov Raykov also recently made the following trade(s):

• On Monday, January 6th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$8.76, for a total value of C$87,552.00.
• On Friday, December 20th, Rostislav Christov Raykov bought 25,000 shares of Fennec Pharmaceuticals stock. The shares were bought at an average price of C$3.87 per share, with a total value of C$96,840.00.
• On Thursday, December 5th, Rostislav Christov Raykov bought 796 shares of Fennec Pharmaceuticals stock. The shares were bought at an average price of C$8.52 per share, with a total value of C$6,779.05.

Fennec Pharmaceuticals Price Performance

Shares of FRX stock traded up C$0.25 on Wednesday, hitting C$9.74. 250 shares of the company’s stock were exchanged, compared to its average volume of 2,334. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. Fennec Pharmaceuticals Inc. has a 12 month low of C$5.65 and a 12 month high of C$15.20. The stock has a market cap of C$266.49 million, a P/E ratio of 97.40 and a beta of 0.25. The company has a 50 day moving average of C$8.75 and a 200 day moving average of C$7.69.

Fennec Pharmaceuticals (TSE:FRX) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported C($0.29) earnings per share for the quarter, missing the consensus estimate of C($0.19) by C($0.10). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. During the same period in the prior year, the company earned ($0.09) EPS. On average, equities research analysts predict that Fennec Pharmaceuticals Inc. will post 0.6037736 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.